Abstract
Cardioversion in atrial fibrillation (AF) is associated with an increased risk of thromboembolism. Current recommendations advise therapy with the anticoagulant warfarin both before and after cardioversion. A new post hoc analysis of data from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial shows that the novel anticoagulant dabigatran is a safe alternative to warfarin in patients with AF who undergo cardioversion.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
